Bogart Wealth LLC’s BridgeBio Pharma BBIO Stock Holding History

Bogart Wealth LLC’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32	Closed	-$2.38K	–	2015
2026 Q1	$2.38K	Sell	32 -32	-50%	-$2.32K	﹤0.01%	1234
2025 Q4	$4.89K	Buy	+64	New	+$4.2K	﹤0.01%	1003

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bogart Wealth LLC's BBIO Position: Q2 2026 in Review

Bogart Wealth LLC sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 32 shares — an estimated $2.38K sold.

Bogart Wealth LLC first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $4.89K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Bogart Wealth LLC reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Bogart Wealth LLC sold 32 BridgeBio Pharma shares in Q2 2026, an estimated $2.38K.
Bogart Wealth LLC first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
Bogart Wealth LLC's BridgeBio Pharma position peaked at $4.89K in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.